Kyle LaHucik covers the financial underpinnings of drug development and breaks news on biotech financing rounds, M&A, IPOs and other deals pushing the industry forward. A graduate of the University of Missouri School of Journalism, Kyle joined Endpoints News in March 2022 after reporting for Fierce Biotech, Mergermarket, Bloomberg, the Columbia Missourian and other publications. Outside of work, catch him on the Chicago lakefront path, where he coaches a local high school cross country and track team, trains for marathons and bikes for fun.